Search

Meeting Coverage:

Caribbean Eye

Caribbean Eye: 2017

New Drug Class Shows Potential for Glaucoma

Jason Bacharach, MD

Show Description +

Jason Bacharach, MD, discussed his excitement regarding results from studies of netarsudil (Aerie), a potential first in a new class of glaucoma medications in 2 decades. The agent was found to be noninferior to timolol in the Rocket 1 and Rocket 2 studies. He also spoke about a fixed-dose agent from the company, PG324, a combination of netarsudil and latanoprost. This would potentially be the first fixed-dose combination drug that contains a prostaglandin available in the United States.

Posted: 2/05/2017

Up Next

$Compounded Medications for Cataract, Refractive, Glaucoma, and DED Patients$

Compounded Medications for Cataract, Refractive, Glaucoma, and DED Patients

Damien Goldberg, MD

Working Smarter, Not Harder!

Working Smarter, Not Harder!

Eric D. Donnenfeld, MD

Don't Wrestle the Pupil!

Don't Wrestle the Pupil!

Johnny Gayton, MD

MIGS Gets Complicated

MIGS Gets Complicated

Ike Ahmed, MD

Femtosecond Laser in High-Risk Patients

Femtosecond Laser in High-Risk Patients

Mark Tomalla, MD

Corneal Inlays: Getting it Right

Corneal Inlays: Getting it Right

Jeff Machat, MD, FRCSC, DABO

Nonimplant Surgery: What Are the Options?

Nonimplant Surgery: What Are the Options?

Karl Stonecipher, MD

LASIK Flap Complications

LASIK Flap Complications

Priyanka Sood, MD

Delivering No-Glasses Vision

Delivering No-Glasses Vision

Jack T. Holladay MD, MSEE, FACS

EDOF Lens Behaves Like a Progressive IOL

EDOF Lens Behaves Like a Progressive IOL

Maria Scott, MD

Good Products, Bad Choices

Good Products, Bad Choices

Doug Katsev, MD

<i>Demodex</i> Blepharitis

Demodex Blepharitis

Anita Nevyas-Wallace, MD

The Iris Protection Plan

The Iris Protection Plan

Denise Visco, MD

Dry Eye Review

Shazia Ahmed, MD

Back to All Videos

New Drug Class Shows Potential for Glaucoma

Jason Bacharach, MD

Jason Bacharach, MD, discussed his excitement regarding results from studies of netarsudil (Aerie), a potential first in a new class of glaucoma medications in 2 decades. The agent was found to be noninferior to timolol in the Rocket 1 and Rocket 2 studies. He also spoke about a fixed-dose agent from the company, PG324, a combination of netarsudil and latanoprost. This would potentially be the first fixed-dose combination drug that contains a prostaglandin available in the United States.

Posted: 2/05/2017

Please log in to leave a comment.

More From Caribbean Eye: 2017 Coverage

Don't Wrestle the Pupil!

Don't Wrestle the Pupil!

Johnny Gayton, MD

MIGS Gets Complicated

MIGS Gets Complicated

Ike Ahmed, MD

Femtosecond Laser in High-Risk Patients

Femtosecond Laser in High-Risk Patients

Mark Tomalla, MD

Corneal Inlays: Getting it Right

Corneal Inlays: Getting it Right

Jeff Machat, MD, FRCSC, DABO